CommercialPrior AuthMedium impact
Oracea (doxycycline, biphasic release)
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Family Medicine, Internal Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their Oracea (doxycycline, biphasic release) policy with revised criteria for prior authorization approval. The policy now extends approval length to 6 months (previously 4 months maximum) and clarifies that sample usage cannot satisfy medical policy requirements for authorization.
Action Required
Immediately: Update prior authorization request procedures for Oracea prescriptions to reflect new 6-month approval length and ensure documentation shows failure of topical treatments and immediate-release doxycycline before requesting authorization. Do not reference sample usage as justification for medical necessity in prior auth requests as this will not be accepted.